Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma group’s core oncology platforms.
Beacon Therapeutics’ gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial’s separately designated European primary efficacy measure were less clear-cut.
Australian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an initial $1.65 billion (€1.44 billion), combining Telix’s commercial radiopharma business with one of Europe’s largest producers of therapeutic radioisotopes.
Dutch biotech Matisse Pharmaceuticals has raised €14 million in a Series A financing to advance isupartob sodium through Phase 2 development in sepsis.
NovartisNovartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the 251-patient Phase 2 ASTRALS trial missed its primary and secondary endpoints, and shortly after Axoltis Pharma suffered a similar Phase 2 setback.
Novartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.
Novo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.
Roche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.
The French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.
Thomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family office, an award bearing their name is turning that investment philosophy into a search for Europe’s next biotech builders.